HS Research Brief: Bimekizumab (Bimzelx, UCB) Provides Sustained Symptom Relief for up to 3 Years
Bimekizumab (Bimzelx, UCB) continues to provide symptom relief in hidradenitis suppurativa (HS) for up to three years, according to new research presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France.